topiramate and ocular syndrome
Last reviewed 01/2018
- an ocular syndrome has been reported associated with the use of topiramate
- the syndrome is characterised by acute myopia and secondary angle-closure
glaucoma
- as of August 17, 2001, there had been 23 reported cases of this ocular
syndrome; 22 in adults and 1 in a paediatric patient. This information was
base on the post marketing experience in more than 825,000 patients (1)
- symptoms of ocular syndrome generally occur within 1 month of the start
of treatment and include decreased visual acuity and/or ocular pain. Ophthalmological
findings include hyperaemia, bilateral myopia, anterior chamber shallowing,
and increased intra-ocular pressure with or without mydriasis. Also there
may also be supraciliary effusion resulting in anterior displacement of lens
and iris. Treatment includes discontinuation of topiramate treatment as rapidly
as is clinically feasible and appropriate measures to reduce intraocular pressure
- please consult summary of product characteristics for more details
Reference:
- (1) Janssen-Cilag Ltd (15/10/2001). Letter - Important Safety Information - Topamax (R) Tablets and Topamax (R) Sprinkle Capsules (Topiramate).